BKPM announces Japanese biopharmaceutical firm Takeda to invest Rp539 billion
The Ministry of Investment and Downstreaming/Investment Coordinating Board (BKPM) has announced that Japanese biopharmaceutical company Takeda will invest up to USD 30 million, or around Rp539 billion, in developing a plasma-derived medicinal product (PODP) ecosystem in Indonesia. This investment represents an initial two-year phase to establish a plasma bank network as the foundation for developing the national plasma industry.
In an official statement confirmed in Jakarta on Tuesday, Minister of Investment and Downstreaming/Head of BKPM Rosan Roeslani said Takeda’s investment reflects growing confidence among global investors in Indonesia’s investment prospects, particularly in the high-tech healthcare industry sector. "This is a strategic investment that not only brings additional capital but also opens opportunities for technology transfer, human resource development, and the creation of high-skilled employment. The government continues to encourage investment that provides added value and strengthens national industrial capacity so that Indonesia can become a manufacturing and healthcare innovation hub in the region," he said.
According to him, this partnership is also aligned with the economic transformation agenda through downstreaming in various strategic sectors, including healthcare, to enhance the competitiveness of national industry and strengthen Indonesia’s position in the global supply chain. He noted that Japan itself is one of Indonesia’s strategic investment partners. Based on the ministry’s records, in the first quarter of 2026, Japan ranked fifth among Indonesia’s top investors, with capital investment reaching USD 1 billion.
Total realised investment from Japan for the period 2021 to the first quarter of 2026 reached USD 18.1 billion, with an average growth of 13.2 percent, absorbing 299,460 workers. According to Rosan, this provides a strong foundation for developing investment cooperation, including in the priority health sector. Through this collaboration, the ministry hopes Indonesia will not only be able to improve public access to much-needed plasma-derived medicinal products but also build a competitive, innovative, and sustainable biopharmaceutical industry ecosystem. The first plasma bank is targeted to begin operations in 2027 as part of the development of a national plasma network that meets global standards.